Ipamorelin 5 mg/Tesamorelin 5 mg: The Ultimate Growth Hormone Synergy Blend
Dragon Pharma introduces a revolutionary peptide combination with its Ipamorelin 5 mg/Tesamorelin 5 mg blend, representing the pinnacle of growth hormone optimization research. This sophisticated formulation pairs two of the most advanced growth hormone secretagogues in a precisely balanced 1:1 ratio, creating a synergistic effect that surpasses what either compound can achieve alone. With third-party laboratory verification confirming 5.47 mg Ipamorelin and 5.33 mg Tesamorelin actual content per vial, researchers can trust the precision and quality of this cutting-edge blend. This combination offers a comprehensive approach to studying body recomposition, with Tesamorelin targeting stubborn adipose tissue and Ipamorelin providing clean, pulsatile GH release.
DRUG DESCRIPTION
Dragon Pharma’s Ipamorelin/Tesamorelin blend is supplied as a sterile, lyophilized powder in a 10 mg / 2 mL vial, containing a precisely calibrated combination of two advanced peptides. Ipamorelin is a third-generation growth hormone-releasing peptide (GHRP) that stimulates GH secretion through ghrelin receptor activation. Its key advantage is exceptional selectivity—it promotes robust GH release without significantly affecting cortisol, prolactin, or ACTH levels. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog specifically engineered with 44 amino acids for enhanced stability and targeted action. It mimics the natural GHRH produced by the hypothalamus and has demonstrated particular efficacy in reducing visceral adipose tissue in research settings. Together, these compounds create a “push-pull” mechanism on the pituitary gland, resulting in amplified, physiological GH pulses that mimic the body’s natural secretion patterns.
IPAMORELIN/TESAMORELIN PROFILE
Drug Class: Growth Hormone Secretagogue Blend
Main Active Substance: Ipamorelin & Tesamorelin
Concentration: 10 mg/vial (5 mg each)
Presentation: 2 mL Vial
Elimination Half-Life: Varies (Ipamorelin ~2h, Tesamorelin ~30min)
Recommended Dosage: 500-1000 mcg total, once daily
Anabolic Ratio: N/A (non-steroidal)
Androgenic Ratio: N/A
Acne: Low risk
Hepatotoxicity: No
Aromatization: No
Manufacturer: Dragon Pharma
LAB TEST REPORT
Dragon Pharma maintains its commitment to transparency and quality with comprehensive third-party testing of the Ipamorelin/Tesamorelin blend. Laboratory analysis conducted on November 10, 2025, verified actual contents of 5.47 mg Ipamorelin (109.4% of labeled) and 5.33 mg Tesamorelin (106.6% of labeled) per vial. The testing utilized advanced HPLC-MS methodology to ensure accurate quantification of both peptides simultaneously, confirming the precise 1:1 ratio essential for the synergistic effect. This independent validation provides researchers with absolute confidence in the blend’s consistency, eliminating concerns about ratio inaccuracies or peptide degradation that could compromise research outcomes involving this sophisticated combination.
HOW TO USE IPAMORELIN/TESAMORELIN BLEND
For research purposes, the Ipamorelin/Tesamorelin 10 mg blend is reconstituted with bacteriostatic water. Research protocols typically involve once-daily administration, usually in the evening before bedtime to align with the body’s natural nocturnal GH pulse. The extended activity of Tesamorelin allows for this convenient dosing schedule while maintaining effective GH elevation. Common research cycles last 12-16 weeks due to the excellent safety profile of both compounds. This blend is frequently researched as part of comprehensive body recomposition stacks. It combines effectively with AOD 9604 5 mg for enhanced fat loss research. For muscle growth studies, it can be stacked with Anavar 10 to create a lean mass building environment. To manage potential nutrient partitioning effects, researchers may include metformin in their metabolic studies. During cutting phases, it can be researched with Clenbuterol for powerful fat loss synergy. For overall wellness and cognitive benefits, it pairs well with Semax 5mg.
POSSIBLE SIDE EFFECTS
The Ipamorelin/Tesamorelin blend is generally well-tolerated in research settings, with side effects typically being mild and transient. The most common effects are related to the initial increase in GH and may include mild joint stiffness, fluid retention, or numbness in extremities due to fluid shifts. Some research subjects report temporary lethargy or increased sleepiness after administration. Unlike other GHRPs, Ipamorelin does not cause significant hunger stimulation, making this blend suitable for cutting research. Tesamorelin’s specific action on visceral fat makes it particularly valuable for metabolic studies without causing the generalized water retention sometimes seen with other GH-secretagogues. Injection site reactions are rare with proper technique. The verified purity and accurate ratio of Dragon Pharma’s formulation ensure consistent effects without the variability that can occur with improperly balanced blends.
CONCLUSION
Dragon Pharma’s Ipamorelin 5 mg/Tesamorelin 5 mg blend represents a significant advancement in peptide research, offering a sophisticated dual-mechanism approach to growth hormone optimization. The combination of Ipamorelin’s clean GH-releasing properties with Tesamorelin’s targeted GHRH action and specific visceral fat reduction capabilities creates a comprehensive tool for body recomposition studies. The third-party verified potency and precise 1:1 ratio ensure researchers receive exactly what’s needed for reproducible results. When implemented within structured research protocols, this blend can yield significant insights into fat loss mechanisms, muscle preservation during caloric deficit, and overall metabolic health. For researchers seeking the benefits of elevated GH levels with minimal side effects and specific action on stubborn adipose tissue, this combination offers an unparalleled research opportunity.
IPAMORELIN/TESAMORELIN FAQ
The combination creates true synergy—Ipamorelin and Tesamorelin work through different receptors and mechanisms (GHRP vs GHRH) to amplify GH release beyond what either can achieve alone. This multi-pathway approach mimics the body’s natural GH regulation more comprehensively than single compounds.
Tesamorelin has demonstrated particular efficacy in reducing visceral adipose tissue through complex mechanisms involving enhanced lipolysis and reduced lipogenesis in abdominal fat deposits. Its action on IGF-1 levels appears to preferentially mobilize stubborn abdominal fat, making it valuable for metabolic syndrome research.
Tesamorelin’s extended half-life (approximately 30 minutes compared to natural GHRH’s 7-10 minutes) allows for sustained stimulation of the pituitary gland. When combined with Ipamorelin’s potent acute release, this creates both immediate and prolonged GH elevation that makes multiple daily administrations unnecessary.
Absolutely. The restoration of youthful GH pulsatility combined with the specific reduction of visceral fat makes this blend particularly valuable for anti-aging studies. The improved body composition and metabolic parameters align closely with markers of youthful physiology. For scientific context on GH axis function, see: National Library of Medicine – Growth Hormone Axis.
Yes, this is one of its key advantages. Ipamorelin is renowned for its selectivity—it stimulates GH release without significant effects on cortisol or prolactin levels. This makes the blend suitable for researchers who may be sensitive to the endocrine effects of other GHRPs like GHRP-6 or Hexarelin.